Clinical trials: Respiratory Function Tests
COPD (Chronic Obstructive Pulmonary Disease)
RETHINC: REdefining THerapy In Early COPD for the Pulmonary Trials Cooperative
The study hypothesis is that symptomatic current and former smokers with spirometric values within the normal range (post-bronchodilator FEV1/FVC≥0.70 and post-BD FVC ≥ 70% predicted will still derive symptomatic benefit from…
- Trial name
- RETHINC (NCT02867761)
- Testing
- Indacaterol/Glycopyrrolate
- Where
- 16 sites in United States
- Volunteers
- 780 people
- Sponsor
- University of Michigan
Laparoscopic Renal Surgery, Laparoscopy
Effects of Deep Neuromuscular Blockade on Intraoperative Respiratory Mechanics
The primary objective of the current study is to compare intraoperative respiratory mechanics in patients receiving laparoscopic renal surgery under deep neuromuscular blockade (dNMB) and under moderate neuromuscular blockade…
- Conditions
- Laparoscopic Renal Surgery, Laparoscopy, Muscle Relaxation
- Trial name
- NCT02185339
- Testing
- Rocuronium
- Where
- South Korea
- Volunteers
- 61 people
- Sponsor
- Seoul St. Mary's Hospital
Cystic Fibrosis
Blood Flow and Vascular Function in Cystic Fibrosis
Cystic fibrosis (CF) has many health consequences. A reduction in the ability to perform exercise in patients with CF is related to greater death rates, steeper decline in lung function, and more frequent lung infections.
- Trial name
- CF-FLOW (NCT02057458)
- Testing
- Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks)
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Augusta University
ALS
Remote Pulmonary Function Testing in Amyotrophic Lateral Sclerosis (Pilot)
The specific objective of this study is to validate the practice of remote pulmonary function testing (rPFT) conducted in the home through the use of connected mobile health devices and the Penn State Hershey ALS Telemanagement…
- Trial name
- NCT03214224
- Testing
- remote pulmonary function testing, standard pulmonary function testing
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Milton S. Hershey Medical Center
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Effect of Noninvasive Ventilation on Lung Function in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), or "Lou Gehrig's Disease", is a fatal disorder that causes progressive degeneration and weakening of the muscles of breathing, leading to breathing insufficiency and eventually breathing…
- Trial name
- NCT00537446
- Testing
- noninvasive positive pressure ventilation
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Columbia University
Bronchopulmonary Dysplasia, Very Low Birth Weight
Preterm Infant Inhaled Albuterol Dosing
The purpose of this study is to help determine the best dose of inhaled albuterol sulfate in premature babies at risk of developing bronchopulmonary dysplasia (BPD).
- Trial name
- NCT02447250
- Testing
- Varied albuterol dose response
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Oregon Health and Science University
Pulmonary Function; Newborn, Abnormal, Infant Wheeze
Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function
Vitamin C supplementation (500 mg per day) given to pregnant women who can not quit smoking will improve the pulmonary function tests in their offspring measured at 3 months of age.
- Conditions
- Pulmonary Function; Newborn, Abnormal, Infant Wheeze, In-utero Nicotine, Second Hand Smoke
- Trial name
- VCSIP (NCT01723696)
- Testing
- Vitamin C +prenatal vitamin
- Where
- 2 sites in United States
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Pulmonary Arterial Hypertension
The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study
The purpose of this study is to find out if spironolactone added to ambrisentan for Pulmonary Arterial Hypertension (PAH) will increase exercise capacity.
- Trial name
- NCT02253394
- Testing
- Ambrisentan plus Spironolactone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Brigham and Women's Hospital
Signs and Symptoms, Respiratory, Mobile Applications
Feasibility Study to Use Biosensing Devices to Monitor PA and Resp. Function in Smokers w and w/o Resp. Symptoms/COPD
This study examines the feasibility and acceptability of using mobile applications and biosensing (mHealth) devices in detecting vitality parameters in current smokers with and without respiratory symptoms/COPD (e.g., heart rate…
- Conditions
- Signs and Symptoms, Respiratory, Mobile Applications, Activity Trackers, Respiratory Function Tests
- Trial name
- NCT04081961
- Testing
- Anamed OEM device; Air Next mobile spirometry device
- Where
- Kazakhstan
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Kazakhstan Academy of Preventive Medicine
Siderosis, Neurological Disorder
Audiovestibular Function in Infratentorial Superficial Siderosis
One in six people in the United Kingdom and over 400 million people worldwide have disabling hearing loss. This figure will double by 2050 as predicted by the World Health Organisation.
- Conditions
- Siderosis, Neurological Disorder, Rare Diseases, Age Related Hearing Loss
- Trial name
- AViSS (NCT04200664)
- Testing
- Hearing assessment, Vestibular/balance assessment, Quality of life assessment
- Where
- 2 sites in United Kingdom
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University College, London
Hypoxemia, Anoxia
Reproducibility of 6 Minute Walk Tests for Oxygen Desaturation
This trial will test the hypothesis that the 6 minute walk test (6MWT) is not reproducible as a measure for oxygen desaturation.
- Conditions
- Hypoxemia, Anoxia, Chronic Obstructive Pulmonary Disease
- Trial name
- 6MWT (NCT00740220)
- Where
- United States
- Volunteers
- 97 people
- Sponsor
- Wake Forest University Health Sciences
Cystic Fibrosis
Study to Evaluate the Safety and Efficacy of Ciprofloxacin (Inhaled) in Patients With Cystic Fibrosis
To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
- Trial name
- NCT00645788
- Testing
- Ciprofloxacin (Cipro Inhale, BAYQ3939)
- Where
- 86 sites in United States, Australia and 7 more
- Volunteers
- 288 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease
Acute Effects of a Flutter Device in COPD
Chronic obstructive pulmonary disease (COPD) is characterised by airflow limitation that is not fully reversible, and is usually progressive and associated with an abnormal inflammatory response of the lungs to noxious particles…
- Trial name
- AEFLUC (NCT01832961)
- Testing
- Flutter valve exercises, Flutter and bronchodilator exercises
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Respiratory Disease
Comparing 6-Minute Walk Tests for Ambulatory Oxygen Assessment
Patients with lung disease who report breathlessness on exertion are often referred for a 6MWT. Due to the nature of the 6MWT (hereon referred to as a Max-6MWT), patients are required to walk as far as they can in 6 minutes.
- Trial name
- NCT05630092
- Testing
- Maximal 6-minute Walk Test (Max_6MWT), Normal speed 6-minute Walk Test (Nor_6MWT)
- Where
- United Kingdom
- Volunteers
- 93 people
- Sponsor
- Hampshire Hospitals NHS Foundation Trust
Chronic Obstructive Pulmonary Disease, COPD
A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
- Trial name
- NCT02449018
- Testing
- QBW251
- Where
- 16 sites in United States, Poland
- Volunteers
- 92 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Investigation of H01 in Adults With Pulmonary Hypertension Including Interstitial Lung Disease (The SATURN Study).
This study is a prospective, randomized, double-blind, study of H01 (Hymecromone) in adults with pulmonary hypertension (PH). The primary objective of this study is to evaluate the safety and tolerability of oral H01 and the…
- Trial name
- SATURN (NCT05128929)
- Testing
- Hymecromone (H01)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Stanford University
COPD
Imaging Regional Lung Defect Severity
The purpose of this study is to develop and evaluate the usefulness of magnetic resonance imaging (MRI) using inert perfluorinated gases mixed with oxygen for regional assessment of pulmonary function.
- Trial name
- DIAL1001004 (NCT01640288)
- Testing
- Perfluorinated Gas/Oxygen Mixture, High Resolution CT of the Chest
- Where
- United States
- Volunteers
- 171 people, healthy volunteers welcome
- Sponsor
- Hal C Charles
Pulmonary Disease, Chronic Obstructive
Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD)
More patients with chronic obstructive pulmonary disease (COPD) die from cardiovascular disease than direct pulmonary complications.
- Trial name
- NCT01398943
- Testing
- Tetrahydrobiopterin (BH4), Antioxidant Cocktail
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Augusta University
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
- Trial name
- NCT02888080
- Testing
- ACZ885
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Spinal Cord Injury
Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
The primary purpose of this study is to determine the effect of administration of the oral beta-2 adrenergic agonist, albuterol, on respiratory muscle strength in individuals with cervical (neck) and high thoracic (upper back)…
- Trial name
- NCT00755079
- Testing
- extended release beta-2 adrenergic agonist
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- US Department of Veterans Affairs